LT3159409T - Antiprasminė nukleorūgštis, skirta panaudoti diušeno raumenų distrofijos gydymui - Google Patents

Antiprasminė nukleorūgštis, skirta panaudoti diušeno raumenų distrofijos gydymui

Info

Publication number
LT3159409T
LT3159409T LTEP15810097.4T LT15810097T LT3159409T LT 3159409 T LT3159409 T LT 3159409T LT 15810097 T LT15810097 T LT 15810097T LT 3159409 T LT3159409 T LT 3159409T
Authority
LT
Lithuania
Prior art keywords
duschenal
antiprasmic
treatment
nucleic acid
distrophy
Prior art date
Application number
LTEP15810097.4T
Other languages
English (en)
Inventor
Naoki Watanabe
Yuuichirou TONE
Shin`ichi TAKEDA
Tetsuya Nagata
Original Assignee
Nippon Shinyaku Co., Ltd.
National Center Of Neurology And Psychiatry
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Shinyaku Co., Ltd., National Center Of Neurology And Psychiatry filed Critical Nippon Shinyaku Co., Ltd.
Publication of LT3159409T publication Critical patent/LT3159409T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3233—Morpholino-type ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/33—Alteration of splicing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/30—Production chemically synthesised
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
LTEP15810097.4T 2014-06-17 2015-06-16 Antiprasminė nukleorūgštis, skirta panaudoti diušeno raumenų distrofijos gydymui LT3159409T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014124157 2014-06-17
PCT/JP2015/067238 WO2015194520A1 (ja) 2014-06-17 2015-06-16 アンチセンス核酸

Publications (1)

Publication Number Publication Date
LT3159409T true LT3159409T (lt) 2020-01-27

Family

ID=54935505

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP15810097.4T LT3159409T (lt) 2014-06-17 2015-06-16 Antiprasminė nukleorūgštis, skirta panaudoti diušeno raumenų distrofijos gydymui

Country Status (30)

Country Link
US (4) US9840706B2 (lt)
EP (3) EP4596047A3 (lt)
JP (6) JP6208349B2 (lt)
KR (1) KR102335810B1 (lt)
CN (2) CN111575282B (lt)
AU (3) AU2015277924B2 (lt)
BR (2) BR112016029369B1 (lt)
CA (1) CA2951221A1 (lt)
CO (1) CO2017000357A2 (lt)
CY (1) CY1122462T1 (lt)
DK (1) DK3159409T3 (lt)
ES (2) ES3027057T3 (lt)
HR (1) HRP20200042T1 (lt)
HU (1) HUE047502T2 (lt)
IL (1) IL249574B (lt)
LT (1) LT3159409T (lt)
MX (2) MX420315B (lt)
MY (2) MY202674A (lt)
PH (1) PH12016502501A1 (lt)
PL (2) PL3159409T3 (lt)
PT (1) PT3159409T (lt)
RS (1) RS59764B1 (lt)
RU (1) RU2695430C2 (lt)
SG (2) SG10201912858VA (lt)
SI (1) SI3159409T1 (lt)
SM (1) SMT202000006T1 (lt)
TW (2) TWI666317B (lt)
UA (1) UA121117C2 (lt)
WO (1) WO2015194520A1 (lt)
ZA (1) ZA201700142B (lt)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015277924B2 (en) * 2014-06-17 2021-02-25 National Center Of Neurology And Psychiatry Antisense nucleic acids
HRP20201125T1 (hr) 2015-09-15 2020-10-30 Nippon Shinyaku Co., Ltd. Antisens nukleinska kiselina
WO2017047741A1 (ja) * 2015-09-16 2017-03-23 日本新薬株式会社 筋萎縮症治療用アンチセンス核酸
EP3359523A4 (en) 2015-10-09 2019-07-24 Wave Life Sciences Ltd. OLIGONUCLEOTIDE COMPOSITIONS AND METHOD THEREFOR
KR102775461B1 (ko) 2016-04-01 2025-02-28 어비디티 바이오사이언시스 인크. 핵산-폴리펩타이드 조성물 및 이의 용도
AU2017290231A1 (en) 2016-06-30 2019-02-07 Sarepta Therapeutics, Inc. Exon skipping oligomers for muscular dystrophy
CN117298290A (zh) 2016-12-19 2023-12-29 萨勒普塔医疗公司 用于肌肉萎缩症的外显子跳跃寡聚体缀合物
LT3554553T (lt) 2016-12-19 2022-08-25 Sarepta Therapeutics, Inc. Egzoną šalinantys oligomero konjugatai nuo raumenų distrofojos
EP3554552B1 (en) 2016-12-19 2022-08-17 Sarepta Therapeutics, Inc. Exon skipping oligomer conjugates for muscular dystrophy
CN110381980A (zh) 2017-01-06 2019-10-25 艾维迪提生物科学有限责任公司 核酸-多肽组合物以及诱导外显子跳读的方法
GB201711809D0 (en) 2017-07-21 2017-09-06 Governors Of The Univ Of Alberta Antisense oligonucleotide
MA50269A (fr) * 2017-09-22 2020-07-29 Avidity Biosciences Inc Compositions d'acides nucléiques-polypeptides et méthodes d'induction de saut d'exon
EA201991450A1 (ru) 2017-09-22 2019-12-30 Сарепта Терапьютикс, Инк. Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии
CN118638788A (zh) 2017-12-06 2024-09-13 艾维迪提生物科学公司 治疗肌萎缩和强直性肌营养不良的组合物和方法
US10758629B2 (en) 2018-05-29 2020-09-01 Sarepta Therapeutics, Inc. Exon skipping oligomer conjugates for muscular dystrophy
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US20220193250A1 (en) 2018-08-02 2022-06-23 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
JP7611825B2 (ja) 2018-08-02 2025-01-10 ダイン セラピューティクス，インコーポレーテッド ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用
IL326747A (en) 2018-11-02 2026-04-01 Biomarin Tech Bv Bispecific antisense oligonucleotides for dystrophin exon skipping
CA3137715A1 (en) 2019-04-25 2020-10-29 Avidity Biosciences, Inc. Nucleic acid compositions and methods of multi-exon skipping
CA3149488A1 (en) * 2019-08-02 2021-02-11 Research Institute At Nationwide Children's Hospital Exon 44-targeted nucleic acids and recombinant adeno-associated virus comprising said nucleic acids for treatment of dystrophin-based myopathies
AU2021226089A1 (en) * 2020-02-28 2022-09-15 National Center Of Neurology And Psychiatry Antisense nucleic acid inducing skipping of exon 51
WO2021188390A1 (en) 2020-03-19 2021-09-23 Avidity Biosciences, Inc. Compositions and methods of treating facioscapulohumeral muscular dystrophy
EP4121088A4 (en) 2020-03-20 2024-07-03 Keros Therapeutics, Inc. Methods of using activin receptor type iib variants
CA3176735A1 (en) 2020-03-20 2021-09-23 Keros Therapeutics, Inc. Activin receptor type ii chimeras and methods of use thereof
CA3216839A1 (en) 2021-04-30 2022-11-03 Sarepta Therapeutics, Inc. Treatment methods for muscular dystrophy
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
CN117980006A (zh) 2021-07-09 2024-05-03 达因疗法公司 用于治疗肌养蛋白病的肌肉靶向复合物和制剂
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US20240390508A1 (en) 2021-08-21 2024-11-28 Takeda Pharmaceutical Company Limited Human transferrin receptor binding peptide-drug conjugate
US20240366775A1 (en) 2021-08-24 2024-11-07 Peptidream Inc. Human transferrin receptor binding antibody-peptide conjugate
MX2024003266A (es) 2021-09-16 2024-04-03 Avidity Biosciences Inc Composiciones y metodos de tratamiento de la distrofia muscular facioescapulohumeral.
KR20240129006A (ko) 2021-12-27 2024-08-27 니뽄 신야쿠 가부시키가이샤 올리고 핵산 화합물의 제조 방법
EP4215614A1 (en) 2022-01-24 2023-07-26 Dynacure Combination therapy for dystrophin-related diseases
EP4230196A1 (en) 2022-02-21 2023-08-23 Som Innovation Biotech, S.A. Compounds for use in the treatment of dystrophinopathies
US20250170259A1 (en) 2022-03-03 2025-05-29 Yale University Compositions and methods for delivering therapeutic polynucleotides for exon skipping
JP2025509438A (ja) 2022-03-17 2025-04-11 サレプタ セラピューティクス， インコーポレイテッド ホスホロジアミデートモルホリノオリゴマーコンジュゲート
US12071621B2 (en) 2022-04-05 2024-08-27 Avidity Biosciences, Inc. Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping
WO2025174995A1 (en) * 2024-02-13 2025-08-21 Keros Therapeutics, Inc. Methods of using activin a and myostatin signaling inhibitors

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0962463B1 (en) 1989-12-20 2002-07-10 Antivirals Inc. Uncharged morpholino-based polymers having phosphorus-containing chiral intersubunit linkages
JP2924179B2 (ja) 1993-02-19 1999-07-26 日本新薬株式会社 グリセロール誘導体，デバイス及び医薬組成物
FR2705361B1 (fr) * 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
US7902160B2 (en) 2002-11-25 2011-03-08 Masafumi Matsuo ENA nucleic acid drugs modifying splicing in mRNA precursor
AU2003225410A1 (en) 2003-03-21 2004-10-11 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
PL1766010T3 (pl) * 2004-06-28 2011-07-29 Univ Western Australia Antysensowne oligonukleotydy do indukcji pominięcia egzonu i sposoby ich zastosowania
EP1857548A1 (en) 2006-05-19 2007-11-21 Academisch Ziekenhuis Leiden Means and method for inducing exon-skipping
JP5143450B2 (ja) * 2007-03-14 2013-02-13 斉 大戸 Ｈｌａ−ｂローカスにおける新規アリル
EP2203173B1 (en) * 2007-10-26 2015-12-23 Academisch Ziekenhuis Leiden Means and methods for counteracting muscle disorders
DK2207779T3 (da) 2007-11-15 2014-07-14 Sarepta Therapeutics Inc Fremgangsmåde til syntese af morpholinooligomerer
EP2119783A1 (en) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
US8084601B2 (en) 2008-09-11 2011-12-27 Royal Holloway And Bedford New College Royal Holloway, University Of London Oligomers
CN105779453A (zh) * 2008-10-24 2016-07-20 萨雷普塔治疗公司 用于dmd的多外显子跳跃组合物
EP2421971B1 (en) 2009-04-24 2016-07-06 BioMarin Technologies B.V. Oligonucleotide comprising an inosine for treating dmd
BR122023023194A2 (pt) 2009-11-12 2023-12-26 The University Of Western Australia Oligonucleotídeo antissentido, composição e respectivo uso
TWI541024B (zh) * 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
CA2826836A1 (en) 2011-02-08 2012-08-16 The Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Medical Center Antisense oligonucleotides
CA3132111A1 (en) 2011-12-28 2013-07-04 Nippon Shinyaku Co., Ltd. Antisense nucleic acids for skipping of exon 55 of human dystrophin gene
CN118581086A (zh) * 2012-01-27 2024-09-03 比奥马林技术公司 用于治疗杜兴型肌营养不良症和贝克型肌营养不良症的具有改善特性的rna调节性寡核苷酸
EP2870246B1 (en) 2012-07-03 2019-09-11 BioMarin Technologies B.V. Oligonucleotide for the treatment of muscular dystrophy patients
JP2014124157A (ja) 2012-12-27 2014-07-07 Nihon Cornstarch Corp コーヒー飲料
RU2730681C2 (ru) 2014-03-12 2020-08-24 Ниппон Синяку Ко., Лтд. Антисмысловые нуклеиновые кислоты
AU2015277924B2 (en) * 2014-06-17 2021-02-25 National Center Of Neurology And Psychiatry Antisense nucleic acids

Also Published As

Publication number Publication date
AU2015277924B2 (en) 2021-02-25
EP3660154A1 (en) 2020-06-03
TW201936922A (zh) 2019-09-16
IL249574B (en) 2021-02-28
AU2024201290A1 (en) 2024-03-21
PH12016502501A1 (en) 2017-03-22
RS59764B1 (sr) 2020-02-28
KR20170017939A (ko) 2017-02-15
NZ765451A (en) 2024-04-26
TWI721461B (zh) 2021-03-11
HUE047502T2 (hu) 2020-04-28
WO2015194520A1 (ja) 2015-12-23
CA2951221A1 (en) 2015-12-23
JP6701139B2 (ja) 2020-05-27
SG10201912858VA (en) 2020-02-27
MX420315B (es) 2025-02-10
MY202674A (en) 2024-05-14
SMT202000006T1 (it) 2020-03-13
ES3027057T3 (en) 2025-06-12
BR112016029369A2 (pt) 2018-01-09
MX373052B (es) 2020-05-11
BR122020020864B1 (pt) 2022-06-21
PT3159409T (pt) 2020-01-21
EP3660154B1 (en) 2025-04-16
EP4596047A2 (en) 2025-08-06
JP2020182459A (ja) 2020-11-12
CO2017000357A2 (es) 2017-06-09
DK3159409T3 (da) 2020-01-27
UA121117C2 (uk) 2020-04-10
EP4596047A3 (en) 2025-10-22
JP2026010142A (ja) 2026-01-21
CN106661577B (zh) 2020-05-12
US20220049257A1 (en) 2022-02-17
HRP20200042T1 (hr) 2020-03-20
SG11201610130VA (en) 2017-01-27
EP3159409A4 (en) 2018-01-10
US20170204410A1 (en) 2017-07-20
CN111575282A (zh) 2020-08-25
AU2015277924A1 (en) 2017-02-02
US20250084412A1 (en) 2025-03-13
JP6208349B2 (ja) 2017-10-04
RU2695430C2 (ru) 2019-07-23
IL249574A0 (en) 2017-02-28
JP2022082539A (ja) 2022-06-02
AU2021203383A1 (en) 2021-06-24
RU2019121781A (ru) 2019-07-22
BR112016029369B1 (pt) 2020-12-08
NZ728103A (en) 2021-11-26
MX2020004417A (es) 2020-08-06
AU2021203383B2 (en) 2023-11-30
SI3159409T1 (sl) 2020-02-28
US20180044675A1 (en) 2018-02-15
MY194170A (en) 2022-11-16
US9840706B2 (en) 2017-12-12
EP3159409B1 (en) 2019-12-04
US12060556B2 (en) 2024-08-13
PL3159409T3 (pl) 2020-05-18
JPWO2015194520A1 (ja) 2017-04-20
MX2016016526A (es) 2017-04-04
CN106661577A (zh) 2017-05-10
ES2765463T3 (es) 2020-06-09
JP7041879B2 (ja) 2022-03-25
ZA201700142B (en) 2020-05-27
PL3660154T3 (pl) 2025-07-28
RU2017101172A3 (lt) 2018-12-24
RU2017101172A (ru) 2018-07-17
US11193125B2 (en) 2021-12-07
TW201625274A (zh) 2016-07-16
KR102335810B1 (ko) 2021-12-03
CN111575282B (zh) 2024-05-14
JP2024023899A (ja) 2024-02-21
EP3159409A1 (en) 2017-04-26
EP3660154C0 (en) 2025-04-16
TWI666317B (zh) 2019-07-21
JP2018027087A (ja) 2018-02-22
CY1122462T1 (el) 2021-01-27

Similar Documents

Publication Publication Date Title
EP3314027A4 (en) THERAPEUTIC OLIGONUCLEOTIDES
LT3334422T (lt) Kanabidiolio rūgšties panaudojimas epilepsijos gydymui
PL3118311T3 (pl) Antysensowny kwas nukleinowy
LT3253865T (lt) Metodai, skirti sustiprinti terapinių imuninių ląstelių veiksmingumą
LT3230281T (lt) 1,3-tiazol-2-ilu pakeisti benzamidai
SI3105328T1 (sl) Multiplo genomsko inženirstvo omogočeno s CRISPR
EP3842103C0 (en) ADJUSTABLE DUMBBELL SYSTEM
LT3882250T (lt) Tetrahidropiranilamino-pirolopirimidinonas, skirtas panaudoti btk nulemtų sutrikimų gydymui
HUE059158T2 (hu) Eljárás pridopidin elõállítására
PT3094237T (pt) Eletrocardiógrafo
LT3390390T (lt) Bipirazolilo dariniai, tinkami naudoti autoimuninių ligų gydymui
EP3286549A4 (en) BIOSENSOR
HRP20190194T1 (hr) 17a,21-diesteri korteksolona, namijenjeni liječenju tumora
DK3231444T3 (da) Ny behandling
EP3156789C0 (en) BIOSENSOR
DK3094731T3 (da) Saccharidmodificerede nukleinsyremolekyler
HUE050944T2 (hu) Kezelési eljárás tradipitant alkalmazásával
DK3215607T3 (da) Phagterapi
DK3204335T3 (da) Elektrokoagulation reaktor
IL256206A (en) Mct4 inhibitors for treating disease
BR112016022976A2 (pt) Métodos para o tratamento de hcv
LT3210973T (lt) Heteroarilo junginiai, skirti akių ligų gydymui
BR112017002318A2 (pt) combinações de fármacos para tratar mieloma múltiplo.
LT3294769T (lt) Daugybinei mielomai (dm) skirtas gydymas
LT3191514T (lt) Ligandai, sustiprinantys gonadotropinų biologinį aktyvumą